Innoviva, Inc. INVA Internal Expenses — Research And Development Expense

Similar metrics at other companies

NRIXInternal research and development expenses — R&D

$57.07M+12.2%

IRONInternal Research And Development — Research And Development Expense

$11.31M+67.6%

ANABInternal Expenses — Research And Development Expense Reversal Excluding Acquired In Process Cost

$15.33M+12.8%

BEAMExternal Research And Development Expenses — Research And Development Expense

$30.08M-12.6%

IBRXReportable Segment — Research and Development Expense, Internal

$47.91M+12.1%

IRONOther Research — Research And Development Expense

$2.17M+18.2%

Questions, answered.

What is Innoviva, Inc.'s internal expenses — research and development expense?

Innoviva, Inc. (INVA) reported internal expenses — research and development expense of $2.64M in Q1 2026.

How has Innoviva, Inc.'s internal expenses — research and development expense changed year-over-year?

Innoviva, Inc.'s internal expenses — research and development expense increased by 95.9% year-over-year, from $1.35M to $2.64M.

What is the long-term trend for Innoviva, Inc.'s internal expenses — research and development expense?

Over 3 years (2022 to 2025), Innoviva, Inc.'s internal expenses — research and development expense has grown at a -30.9% compound annual growth rate (CAGR), from $16.77M to $5.53M.

What does internal expenses — research and development expense mean?

This metric represents the internal costs incurred by the company to support research and development activities within its specific operating segments. It captures the investment directed toward the discovery, clinical development, and regulatory advancement of the company's healthcare and pharmaceutical assets. Monitoring this expense helps investors evaluate the company's commitment to innovation and the sustainability of its product pipeline.